Analysis of 3,199 clinical trials in Australia from 2012 to 2016 found that Phase III trials outnumbered all other trials overall, making up 33–41% of the trial types during the period, according to GlobalData, a leading data and analytics company.
The share of Phase II trials came second, ranging from 29–37%, and hitting its lowest percentage in 2013. The share of Phase I trials increased from 12% up to 18% over the five-year period, whereas Phase IV trials decreased from 18% in 2012 to 11% in 2016.
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.